IceCure Medical details China patent allowance in SEC report

Rhea-AI Filing Summary

IceCure Medical Ltd. reported that it issued a press release on December 5, 2025 titled “IceCure Receives Notice of Patent Allowance in China for a Novel Cryogen Flow Control to Optimize Patient Cryoablation Outcomes.” This indicates the company has received a notice of patent allowance in China for technology related to cryogen flow control, which is intended to optimize patient cryoablation outcomes.

The press release, excluding its third paragraph, is incorporated by reference into IceCure’s existing Form F-3 and Form S-8 registration statements, meaning the disclosure becomes part of those securities offering documents from the date of this report.

FAQ

AI-generated questions and answers. How Rhea-AI works. Not financial advice.

What did IceCure Medical Ltd. (ICCM) report in this Form 6-K?

IceCure Medical Ltd. reported that it issued a press release on December 5, 2025 announcing a notice of patent allowance in China for a novel cryogen flow control aimed at optimizing patient cryoablation outcomes.

What is the subject of IceCure Medical’s new patent allowance in China?

The patent allowance in China relates to a novel cryogen flow control designed to optimize patient cryoablation outcomes, as described in the title of the attached press release.

How is the December 5, 2025 IceCure press release used in SEC filings?

The press release attached as Exhibit 99.1, excluding its third paragraph, is incorporated by reference into IceCure’s registration statements on Form F-3 and Form S-8, making it part of those documents from the date of this report.

Which IceCure registration statements are affected by this Form 6-K?

The disclosure is incorporated into IceCure’s Form F-3 registration statements (File Nos. 333-258660, 333-267272, 333-290046) and Form S-8 registration statements (Nos. 333-270982, 333-264578, 333-262620, 333-281587).

Who signed this IceCure Medical Ltd. Form 6-K?

The report was signed on behalf of IceCure Medical Ltd. by Eyal Shamir, who is identified as the company’s Chief Executive Officer, dated December 5, 2025.

AI-generated analysis. How Rhea-AI works. Not financial advice.

Form 6-K: How Foreign Companies Report to the SEC →

See more from StockTitan in Google Search and AI answers. Adds StockTitan as a preferred source · opens Google

Add on Google Not now

Accepted by SEC EDGAR 12/05/2025 - 08:45 AM Learn about SEC filing dates

UNITED STATES

SECURITIES AND EXCHANGE COMMISSION

Washington, D.C. 20549

FORM 6-K

REPORT OF FOREIGN PRIVATE ISSUER

PURSUANT TO RULE 13a-16 OR 15d-16

UNDER THE SECURITIES EXCHANGE ACT OF 1934

For the Month of: December 2025 (Report No. 2)

Commission File Number: 001-40753

ICECURE MEDICAL LTD.

(Translation of registrant’s name into English)

7 Ha’Eshel St., PO Box 3163

Caesarea, 3079504 Israel

(Address of principal executive office)

Indicate by check mark whether the registrant files or will file annual reports under cover of Form 20-F or Form 40-F:

☒ Form 20-F             ☐ Form 40-F

CONTENTS

On December 5, 2025, IceCure Medical Ltd. (the “Company”) issued a press release titled “IceCure Receives Notice of Patent Allowance in China for a Novel Cryogen Flow Control to Optimize Patient Cryoablation Outcomes,” a copy of which is furnished as Exhibit 99.1 with this Report of Foreign Private Issuer on Form 6-K. 

The press release attached herewith as Exhibit 99.1 (excluding the third paragraph thereof) is incorporated by reference into the Company’s Registration Statements on Form F-3 (File Nos. 333-258660, 333-267272 and 333-290046) and Form S-8 (Registration Nos. 333-270982, 333-264578, 333-262620 and 333-281587), filed with the Securities and Exchange Commission, to be a part thereof from the date on which this Report of Foreign Private Issuer on Form 6-K is submitted, to the extent not superseded by documents or reports subsequently filed or furnished.

1

EXHIBIT INDEX

Exhibit No.
99.1		Press release dated December 5, 2025 titled “IceCure Receives Notice of Patent Allowance in China for a Novel Cryogen Flow Control to Optimize Patient Cryoablation Outcomes”.

2

SIGNATURES

Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned, thereunto duly authorized.

	ICECURE MEDICAL LTD.
Date: December 5, 2025	By:	/s/ Eyal Shamir
		Name:	Eyal Shamir
		Title:	Chief Executive Officer

3